Carl L. Gordon Insider Trades
DirectorDirector at BlossomHill Therapeutics, Inc. and 1 other company. 2 significant open-market trades reported on SEC Form 4 in the last 180 days.
$25.0M
Bought
$0
Sold
2 / 0
Buys / Sells
2
Companies
Companies
Reported Trades
Open-market transactions only (code P and S), outside any 10b5-1 plan, dated by the day the filing reached EDGAR. Each row links to the filing.
Other Insiders at These Companies
Everyone else who reported a significant open-market trade at the same companies in the last 180 days. Several buyers inside one week is cluster buying.
- Orbimed Advisors LLCDirector at BLSM1 buy, $10.0M
- OrbiMed Capital GP Viii LLCDirector at BLSM1 buy, $10.0M
- John P. SchmidDirector at BLSM1 buy, $96K
- Bihua ChenDirector at BLSM1 buy, $5.0M
- Cormorant Asset Management, LP10% owner at BLSM1 buy, $5.0M
- Cormorant Global Healthcare Master Fund, LP10% owner at BLSM1 buy, $5.0M
- Cormorant Private Healthcare Fund III LP10% owner at BLSM1 buy, $5.0M
- Cormorant Private Healthcare Fund V LP10% owner at BLSM1 buy, $5.0M
- Cormorant Private Healthcare Fund Vi, LP10% owner at BLSM1 buy, $5.0M
- Vincent Paul LiptakGeneral Counsel at BLSM1 buy, $75K
- Marc L. Andreessen10% owner at SCTX1 buy, $5.0M
- Benjamin A. Horowitz10% owner at SCTX1 buy, $5.0M
How to Read This Page
These are the trades an insider chose to make with their own money, not grants, option exercises or tax withholding. A purchase is the stronger signal (why buys carry more information than sales), and an insider who buys is locked out of selling for six months by the short-swing rule. Several insiders buying at the same company in the same week is cluster buying, the pattern the research literature rates highest. The window here is 180 days; the full filing history lives on EDGAR.
Get this insider's next buy the minute it files
InsiderWatch reads every Form 4 as it reaches EDGAR, keeps the open-market buys that matter, and sends them by email and Telegram.
Try free for 7 daysEvery call scored in public, misses included.